ArticleAmerican journal of respiratory and critical care medicine2017
Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.
Article in American journal of respiratory and critical care medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 84 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Eosinophilic Airway Inflammation: Relationship to Remodeling and Modulation by Mepolizumab
Effect of Mepolizumab on the Phenotype/Proteome/Transcriptome of Eosinophils in Severe Eosinophilic Asthma
Who cites it
84 citing papers in PubMed, 2 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- Pooled it
- Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis.Respiratory research · 2019Pooled it
- Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial.The European respiratory journal · 2024Trial
- Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker-high and -low severe asthma.Allergy · 2022Trial
- Reply to: Is the role of eosinophils in refractory chronic cough truly dismissed? Mepolizumab reduced blood and sputum eosinophils, but not eosinophil-derived neurotoxin.The European respiratory journal · 2026Article
- Pro-inflammatory and counter-regulatory modulators of interleukin-5-driven eosinophil programs: a framework for precision medicine in eosinophilic diseases.Frontiers in immunology · 2026Review
- Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.Frontiers in immunology · 2026Review
- Integrated pro-resolving mechanisms: a new dimension for optimizing anti-inflammatory therapy in asthma - a review of impaired inflammation resolution in airway remodeling.Frontiers in immunology · 2026Review
- Single-cell transcriptomics of granulocytes in asthma and atopic diseases.Frontiers in molecular biosciences · 2026Review
- Mouse TThe Journal of allergy and clinical immunology · 2025Article
- Established and Emerging Asthma Biomarkers with a Focus on Biologic Trials: A Narrative Review.Journal of personalized medicine · 2025Review
- The Role of Endobronchial Biopsies in Evaluating Biologic Therapy Response in Severe Asthma.International journal of molecular sciences · 2025Review
- Benralizumab Depletes IL-5Rα-Bearing Cells in Skin Lesions of Patients With Atopic Dermatitis.Clinical and translational allergy · 2025Article
- Article
- Identification of bronchial epithelial genes associated with type 2 eosinophilic inflammation in asthma.The Journal of allergy and clinical immunology · 2025Article
- A method for MRI-guided bronchoscopy to identify obstructed airway segments.Physiological reports · 2025Article
- The Effect of Mepolizumab on Blood Eosinophil Subtype Distribution and Granule Protein Gene Expression in Severe Eosinophilic Asthma.Journal of asthma and allergy · 2025Article
- Antiviral roles of eosinophils in asthma and respiratory viral infection.Frontiers in allergy · 2025Review
- Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma.Frontiers in immunology · 2025Article
- Eosinophil specialization is regulated by exposure to the esophageal epithelial microenvironment.Journal of leukocyte biology · 2024Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
rationaleMepolizumab, an IL-5-blocking antibody, reduces exacerbations in patients with severe eosinophilic asthma. Mepolizumab arrests eosinophil maturation; however, the functional phenotype of eosinophils that persist in the blood and airway after administration of IL-5 neutralizing antibodies has not been reported.
objectivesTo determine the effect of anti-IL-5 antibody on the numbers and phenotypes of allergen-induced circulating and airway eosinophils.
methodsAirway inflammation was elicited in participants with mild allergic asthma by segmental allergen challenge before and 1 month after a single intravenous 750-mg dose of mepolizumab. Eosinophils were examined in blood, bronchoalveolar lavage, and endobronchial biopsies 48 hours after challenge. MEASUREMENTS AND MAIN
resultsSegmental challenge without mepolizumab induced a rise in circulating eosinophils, bronchoalveolar lavage eosinophilia, and eosinophil peroxidase deposition in bronchial mucosa. IL-5 neutralization before allergen challenge abolished the allergen-induced rise in circulating eosinophils and expression of IL-3 receptors, whereas airway eosinophilia and eosinophil peroxidase deposition were blunted but not eliminated. Before mepolizumab treatment, bronchoalveolar lavage eosinophils had more surface IL-3 and granulocyte-monocyte colony-stimulating factor receptors, CD69, CD44, and CD23 and decreased IL-5 and eotaxin receptors than blood eosinophils. This activation phenotype indicated by bronchoalveolar lavage eosinophil surface markers, as well as the release of eosinophil peroxidase by eosinophils in the bronchial mucosa, was maintained after mepolizumab.
conclusionsMepolizumab reduced airway eosinophil numbers but had a limited effect on airway eosinophil activation markers, suggesting that these cells retain functionality. This observation may explain why IL-5 neutralization reduces but does not completely eradicate asthma exacerbations. Clinical trial registered with www.clinicaltrials.gov (NCT00802438).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.